opioids

Opioid Facts and Figures

Created by
International Nurses Society on Addictions (IntNSA)

Opioid Facts and Figures, recorded 3-June-2022. Presented by Lauran Wirf, DO: Addiction Medicine Fellow; University of Colorado School of Medicine; Denver, Colorado. With the increasing prevalence of illicit fentanyl, it is important for healthcare providers to understand the new hurdles they may face in treatment of opioid use disorders.

Modeling the evolution of the US opioid crisis for national policy development

Citation
Yang Lim, T, et al. (2022). Modeling the evolution of the US opioid crisis for national policy development. Proceedings of the National Academy of Sciences, 119(23). https://www.pnas.org/doi/10.1073/pnas.2115714119
Publication Date
Abstract

The opioid crisis is a major public health challenge in the United States, killing about 70,000 people in 2020 alone. Long delays and feedbacks between policy actions and their effects on drug-use behavior create dynamic complexity, complicating policy decision-making.

Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial

Citation
Janzow, G. E., Harding, C., Flores, M., Borodovsky, J., Steinkamp, J., Marsch, L. A., & Schuman-Olivier, Z. (2022). Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial. Drug and Alcohol Dependence Reports, 3, 100045.

Abstract

Background

Increasing buprenorphine/naloxone (B/N) access for opioid use disorder (OUD) is essential yet ensuring adherence and preventing diversion remains challenging. This study examines the feasibility, usability, and acceptability of MySafeRx, a mobile platform integrating motivational coaching, adherence monitoring, and electronic dispensing during office-based B/N treatment.

Opioid Use Disorder in the Nursing Profession

Created by
International Nurses Society on Addictions (IntNSA)

Presented by Kristin Waite-Labott, RN, BSN, CARN; April Lynn Lenzmeier, RN, DNP; Rachel Shuster, BSN, RN, CARN, CAAP. The American Nurses Association estimates that six to eight percent of nurses use alcohol or drugs to an extent that is sufficient to impair professional performance. Others estimate that nurses generally misuse drugs and alcohol at nearly the same rate (10 to 15 percent) as the rest of the population.

Promoting sustainable responses to the US opioid epidemic with community-academic partnerships: qualitative outcomes from a statewide program

Citation
L.Driscoll, D., Cuellar, A.E., Agarwal, V. et al. Promoting sustainable responses to the US opioid epidemic with community-academic partnerships: qualitative outcomes from a statewide program. Subst Abuse Treat Prev Policy 17, 26 (2022). https://doi.org/10.1186/s13011-022-00454-6
Publication Date

Abstract

Background

Drug overdose deaths in the United States have continued to increase at an alarming rate. The Substance Abuse and Mental Health Services Administration (SAMHSA) distributed more than $7 billion between January 2016 and June 2020 to address the drug overdose crisis.

Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community

Citation
Biondi, B.E., Vander Wyk, B., Schlossberg, E.F. et al. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addict Sci Clin Pract 17, 15 (2022). https://doi.org/10.1186/s13722-022-00299-1
Publication Date

Abstract

Background

Medication treatment for opioid use disorder (OUD) (MOUD; buprenorphine and methadone) reduces opioid use and overdose. Discontinuation of MOUD can quickly lead to relapse, overdose and death. Few persons who initiate MOUD are retained on treatment, thus it is critical to identify factors associated with retention.

Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors

Citation
Yunusa I, Gagne JJ, Yoshida K, Bykov K. Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. JAMA Netw Open. 2022;5(2):e220194. doi:10.1001/jamanetworkopen.2022.0194
Publication Date
Abstract

Importance  Some selective serotonin reuptake inhibitors (SSRIs) inhibit the enzymes responsible for the metabolism of oxycodone, a potent prescription opioid. The clinical consequences of this interaction on the risk of opioid overdose have not been elucidated.

Methadone maintenance treatment

Published by
Ministerio de Salud y Protección Social de Colombia
Publication Date

Document of the Ministry of Health and Social Protection of Colombia that presents baseline of the maintenance programs with methadone in the country and the profile of the population served and the general characteristics of the treatment, as well as recommendations in public health for the strengthening of these programs.

Evidence-Based Approaches to Opioid Overdose Recognition and Management: Share the Facts – Save Lives

Publication Date
To mark International Overdose Awareness Day on 31st of August 2021, the International Society of Substance Use Professionals (ISSUP), in collaboration with the United Nations Office on Drugs and Crime (UNODC) and the World Health Organization, presented an online event profiling naloxone programmes as a pathway for improving outcomes in the treatment of opioid dependence, overdose reduction, and saving lives.